NFL Biosciences
Develops botanical drug candidates to treat smoking and alcohol addictions.
ALNFL | PA
Overview
Corporate Details
- ISIN(s):
- FR0014003XO1 (+1 more)
- LEI:
- 9695006VJWNTN4UNHA27
- Country:
- France
- Address:
- 199 RUE HELENE BOUCHER, 34170 CASTELNAU-LE-LEZ
- Website:
- https://www.nflbiosciences.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead asset is NFL-101, an innovative drug candidate for smoking cessation derived from a nicotine-free protein extract of tobacco leaves. Its pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences operates with an outsourced research model, focusing on advancing its products through preclinical and clinical studies. The company's primary business strategy is to license its developed drug candidates to larger pharmaceutical companies for final commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-01-30 08:00 |
NFL BIOSCIENCES : SUCCÈS DE L’ÉTUDE AVEC LE CEA
|
French | 743.3 KB | ||
| 2024-01-12 17:45 |
NFL BIOSCIENCES CONFIRME SON ÉLIGIBILITÉ AU DISPOSITIF PEA-PME
|
French | 66.7 KB | ||
| 2024-01-09 17:45 |
NFL BIOSCIENCES: FINANCIAL CALENDAR FOR 2024
|
English | 165.8 KB | ||
| 2024-01-09 17:45 |
NFL BIOSCIENCES : AGENDA DE COMMUNICATION FINANCIÈRE 2024
|
French | 173.4 KB | ||
| 2024-01-08 17:45 |
NFL BIOSCIENCES : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ 2ème SEMESTRE 2023
|
French | 1.0 MB | ||
| 2023-12-19 08:00 |
NFL BIOSCIENCES: PRE-IND APPLICATION FILED WITH THE FDA IN THE UNITED STATES FO…
|
English | 69.4 KB | ||
| 2023-12-19 08:00 |
NFL BIOSCIENCES : DÉPÔT D’UNE DEMANDE DE PRE-IND AUPRÈS DE LA FDA AUX ÉTATS-UNI…
|
French | 72.2 KB | ||
| 2023-10-06 18:20 |
NFL BIOSCIENCES : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2023
|
French | 2.1 MB | ||
| 2023-10-05 19:00 |
NFL BIOSCIENCES: 2023 FIRST-HALF BUSINESS AND EARNINGS UPDATE
|
English | 466.4 KB | ||
| 2023-10-05 19:00 |
NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023
|
French | 499.6 KB | ||
| 2023-09-25 08:00 |
NFL BIOSCIENCES: PROMISING RESULTS OF THE PRECESTO CLINICAL TRIAL REVEALING A P…
|
English | 757.6 KB | ||
| 2023-09-25 08:00 |
NFL BIOSCIENCES : RESULTATS PROMETTEURS DE L'ETUDE CLINIQUE PRECESTO REVELANT U…
|
French | 868.0 KB | ||
| 2023-07-18 08:00 |
NFL BIOSCIENCES : DÉPÔT D’UNE DEMANDE DE BREVET AUX ÉTATS-UNIS DÉDIÉE À LA RÉDU…
|
French | 153.5 KB | ||
| 2023-07-18 08:00 |
Nfl Biosciences: Patent Application Filed in the United States for Reducing Alc…
|
English | 144.2 KB | ||
| 2023-07-11 17:45 |
NFL BIOSCIENCES CONFIRME LE RENOUVELLEMENT DE SON ELIGIBILITE AU PEA-PME
|
French | 205.0 KB |
Automate Your Workflow. Get a real-time feed of all NFL Biosciences filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NFL Biosciences
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NFL Biosciences via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
